search
Back to results

IVUS Guided PCI for CKD to Reduce CI-AKI (IVUS-CKD)

Primary Purpose

Coronary Artery Disease, Chronic Kidney Diseases

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
IVUS based ultralow contrast PCI
Sponsored by
Jilin University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring CKD, IVUS, CAD, PCI

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: - age over 18 years coronary artery disease referred for percutaneous intervention, with stent, Drug coated bloon, or bioresorbable stent, of one or more epicardial vessel. target lesion must be assessable by IVUS at baseline and during the procedure. 60ml/min/1.73m2<=Baseline Calculated creatinine clearance >=15ml/min/1.73m2 consent can be obtained and comply with all study procedures. Exclusion Criteria: - Use of >50ml of iodinated agent<72 hours Planned used of iodinated contrast within 72 hours after the index procedure use of other nephrotoxic agents<7 days known allergy to contrast agents unstable or unknown renal function prior to PCI life expectancy less than 1 year

Sites / Locations

  • Jilin university
  • Zhongshan Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

IVUS based ultra-low contrast PCI

Standard of care PCI

Arm Description

IVUS based ultra-low contrast PCI

Guideline directed contrast induced nephropathy provention strategy with standard of care PCI procedure.

Outcomes

Primary Outcome Measures

Contrast-induced acute kidney injury
Evaluate whether IVUS-guided PCI reduces CI-AKI. CI-AKI defined as an increase in serum creatine>=0.5mg /dl from the baseline, within 72 hours after the index procedure(or at discharge) comparison to stand-alone angiography-guided PCI. CI-AKI will be defined as an increase in serum creatinine ≥ 0.3 mg/dl (26.52umol)from the baseline value

Secondary Outcome Measures

Major adverse cardiac events and components
cardiovascular death, myocardial infarction and target vessel Revascularization
stent thrombosis
stents thrombosis will be defines as the occurrence of definite or probably stent thrombosis according to the ARC criteria
serious acute kidney dysfunction
>=2mg /dl increase of serum creatine or need for dialysis
procedure time
procedure time from gain access to finish the procedure
radiation exposure
total radiation exposure dose

Full Information

First Posted
June 13, 2023
Last Updated
June 13, 2023
Sponsor
Jilin University
Collaborators
Shanghai Zhongshan Hospital, Zhongnan Hospital, Zhongshan People's Hospital, Guangdong, China, The Sixth People's Hospital of Zhengzhou, China-Japan Union Hospital, Jilin University, First Affiliated Hospital Xi'an Jiaotong University
search

1. Study Identification

Unique Protocol Identification Number
NCT05913362
Brief Title
IVUS Guided PCI for CKD to Reduce CI-AKI
Acronym
IVUS-CKD
Official Title
IVUS Based Ultra-low Volume Contrast Media PCI to Reduce Contrast Induced Nephrology in Patient With Chronic Kidney disease-a Multi-center, Open Label, Randomized Trial (IVUS-CKD)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2023 (Anticipated)
Primary Completion Date
October 1, 2024 (Anticipated)
Study Completion Date
October 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jilin University
Collaborators
Shanghai Zhongshan Hospital, Zhongnan Hospital, Zhongshan People's Hospital, Guangdong, China, The Sixth People's Hospital of Zhengzhou, China-Japan Union Hospital, Jilin University, First Affiliated Hospital Xi'an Jiaotong University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients with Chronic kidney disease are most vulnerable to contrast induced nephropathy after Percutaneous coronary intervention, intravascular ultrasound guidance can be used to safely guide the procedure to reduce the contrast usage, this randomized trial is design to test the hypothesis that IVUS based ultra-low contrast PCI is feasible and can reduce the contrast induced nephropathy.
Detailed Description
Prospective, open-label, randomized(1:1), multi-center trial of 320 patients allocated to one of the treatment arms(IVUS-guided ultra-low contrast PCI or angiography-guided PCI). The study population will be composed of patients with renal dysfunction referring for PCI on one to more coronary artery. target lesion must be assessable with IVUS. eGFR will be re-evaluated 48 hours after the procedure. and at 1 month, 3 month, 6 month, 12 month. as well as follow-up for other clinical outcomes unless contra-indicated all patients will receive intravenous hydration 12 hours before and after the procedure. saline infusion at a dose of 1ml/kg/hour. if with reduced ejection fraction or overt heart failure reduce the saline infusion to 0.5ml/kg/hour. the use of sodium bicarbonate and diuretic will be left at the discretion of the operator All procedure will be performed using non-ionic, low osmolar or iso-osmolar, iodine-based contrast media the study groups will be compared according to the intention-to-treat principle. Categorial variables will be compared by Fisher's exact test and continuous variables by students T test. Time-dependent events will be estimated by the Kaplan-Meier method and compared by hazards cox model or log-rank test.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Chronic Kidney Diseases
Keywords
CKD, IVUS, CAD, PCI

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
320 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IVUS based ultra-low contrast PCI
Arm Type
Experimental
Arm Description
IVUS based ultra-low contrast PCI
Arm Title
Standard of care PCI
Arm Type
No Intervention
Arm Description
Guideline directed contrast induced nephropathy provention strategy with standard of care PCI procedure.
Intervention Type
Behavioral
Intervention Name(s)
IVUS based ultralow contrast PCI
Intervention Description
IVUS based ultralow contrast PCI
Primary Outcome Measure Information:
Title
Contrast-induced acute kidney injury
Description
Evaluate whether IVUS-guided PCI reduces CI-AKI. CI-AKI defined as an increase in serum creatine>=0.5mg /dl from the baseline, within 72 hours after the index procedure(or at discharge) comparison to stand-alone angiography-guided PCI. CI-AKI will be defined as an increase in serum creatinine ≥ 0.3 mg/dl (26.52umol)from the baseline value
Time Frame
within 72 hours after the index procedure (or at discharge).
Secondary Outcome Measure Information:
Title
Major adverse cardiac events and components
Description
cardiovascular death, myocardial infarction and target vessel Revascularization
Time Frame
1 year
Title
stent thrombosis
Description
stents thrombosis will be defines as the occurrence of definite or probably stent thrombosis according to the ARC criteria
Time Frame
1 year
Title
serious acute kidney dysfunction
Description
>=2mg /dl increase of serum creatine or need for dialysis
Time Frame
1 year
Title
procedure time
Description
procedure time from gain access to finish the procedure
Time Frame
1 day
Title
radiation exposure
Description
total radiation exposure dose
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - age over 18 years coronary artery disease referred for percutaneous intervention, with stent, Drug coated bloon, or bioresorbable stent, of one or more epicardial vessel. target lesion must be assessable by IVUS at baseline and during the procedure. 60ml/min/1.73m2<=Baseline Calculated creatinine clearance >=15ml/min/1.73m2 consent can be obtained and comply with all study procedures. Exclusion Criteria: - Use of >50ml of iodinated agent<72 hours Planned used of iodinated contrast within 72 hours after the index procedure use of other nephrotoxic agents<7 days known allergy to contrast agents unstable or unknown renal function prior to PCI life expectancy less than 1 year
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mingyou Zhang, PHD
Phone
13689842200
Email
zmy@jlu.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mingyou Zhang
Organizational Affiliation
Jilin University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jilin university
City
Chang chun
State/Province
Jilin
ZIP/Postal Code
130000
Country
China
Facility Name
Zhongshan Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chenguang Li, PHD
Phone
13816767665
Email
li.chenguang@zs-hospital.sh.cn

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27659469
Citation
McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, Mehta A. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016 Sep 27;68(13):1465-1473. doi: 10.1016/j.jacc.2016.05.099.
Results Reference
background
PubMed Identifier
31473019
Citation
Rudnick MR, Leonberg-Yoo AK, Litt HI, Cohen RM, Hilton S, Reese PP. The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk? Am J Kidney Dis. 2020 Jan;75(1):105-113. doi: 10.1053/j.ajkd.2019.05.022. Epub 2019 Aug 28.
Results Reference
background
PubMed Identifier
25326742
Citation
Mariani J Jr, Guedes C, Soares P, Zalc S, Campos CM, Lopes AC, Spadaro AG, Perin MA, Filho AE, Takimura CK, Ribeiro E, Kalil-Filho R, Edelman ER, Serruys PW, Lemos PA. Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial. JACC Cardiovasc Interv. 2014 Nov;7(11):1287-93. doi: 10.1016/j.jcin.2014.05.024. Epub 2014 Oct 15.
Results Reference
background

Learn more about this trial

IVUS Guided PCI for CKD to Reduce CI-AKI

We'll reach out to this number within 24 hrs